Evidence map›Paper›PMID 41513729›Full record

ArticleScientific reports2026

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study.

Jae Ryong Song, Un Chul Park, Christopher Seungkyu Lee, Jae Jin Cho, Jin Young Kim, Seung Chul Baek, Areum Jeong, Ashish Sharma, Jae Hui Kim, Min Sagong and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jae Ryong Song *Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Un Chul Park *Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Christopher Seungkyu Lee *Institute of Vision Research, Department of Ophthalmology, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jae Jin ChoDepartment of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea.
Jin Young KimInstitute of Vision Research, Department of Ophthalmology, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Seung Chul BaekDepartment of Ophthalmology, Yeungnam Eye Center, Yeungnam University Medical Center, Yeungnam University College of Medicine, 170, Hyunchung-ro, Nam-gu, Daegu, 42415, South Korea.
Areum JeongDepartment of Ophthalmology, Yeungnam Eye Center, Yeungnam University Medical Center, Yeungnam University College of Medicine, 170, Hyunchung-ro, Nam-gu, Daegu, 42415, South Korea.
Ashish SharmaLotus Eye Hospital and Institute, Coimbatore, TN, India.
Jae Hui KimDepartment of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea. kimoph@gmail.com.
Min SagongDepartment of Ophthalmology, Yeungnam Eye Center, Yeungnam University Medical Center, Yeungnam University College of Medicine, 170, Hyunchung-ro, Nam-gu, Daegu, 42415, South Korea. msagong@yu.ac.kr.
Se Joon WooDepartment of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggido, 13620, South Korea. sejoon1@snu.ac.kr.
International Retina Biosimilar Study Group (Inter BIOS Group)

Funding

Ministry of Health and Welfare RS-2024-00512384
6 · The paper itself

Abstract

This study aims to investigate efficacy and safety of ranibizumab biosimilars (Amelivu

Indexed as

Angiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabRetinal DiseasesAgedFemaleHumansIntravitreal InjectionsMacular DegenerationMacular EdemaMaleMiddle AgedRepublic of KoreaRetrospective StudiesTreatment OutcomeVisual AcuityAngiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabAnti-VEGF agentsBiosimilarsDiabetic macular edemaNeovascular age-related macular degenerationRetinal vein occlusion

Identifiers

PMID41513729
PMCPMC12859025

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.